



(11) **EP 2 807 191 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C07K 16/24 ^(2006.01)

(86) International application number:
PCT/GB2013/050162

(48) Corrigendum issued on:
16.10.2019 Bulletin 2019/42

(87) International publication number:
WO 2013/110945 (01.08.2013 Gazette 2013/31)

(45) Date of publication and mention
of the grant of the patent:
10.07.2019 Bulletin 2019/28

(21) Application number: **13702262.0**

(22) Date of filing: **25.01.2013**

(54) **METHODS OF TREATING PAIN BY INHIBITION OF VGF ACTIVITY**

VERFAHREN ZUR BEHANDLUNG VON SCHMERZEN MITTELS HEMMUNG DER VGF-AKTIVITÄT
MÉTHODES DE TRAITEMENT DE LA DOULEUR PAR LE BIAIS DE L'INHIBITION DE L'ACTIVITÉ
DU VGF

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **26.01.2012 GB 201201332**

(43) Date of publication of application:
03.12.2014 Bulletin 2014/49

(73) Proprietor: **Imperial College Innovations Limited**
London SW7 2AZ (GB)

(72) Inventors:
• **OKUSE, Kenji**
London SW7 2AZ (GB)
• **PRISTERA, Alessandro**
London N22 6SU (GB)
• **RICE, Andrew**
London SW10 9NH (GB)

(74) Representative: **Sterling IP**
Orion House
Bessemer Road
Welwyn Garden City AL7 1HH (GB)

(56) References cited:
WO-A1-01/07074 WO-A2-03/016475

- **RIZZI R ET AL: "The VGF-derived peptide TLQP-21: A new modulatory peptide for inflammatory pain", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 441, no. 1, 15 August 2008 (2008-08-15), pages 129-133, XP022822351, ISSN: 0304-3940, DOI: 10.1016/J.NEULET.2008.06.018 [retrieved on 2008-06-12]**
- **Moss et al.: "Origins, actions and dynamic expression patterns of the neuropeptide VGF in rat peripheral and central sensory neurones following peripheral nerve injury", Molecular Pain, vol. 4, no. 62 10 December 2008 (2008-12-10), pages 1-12, XP002695039, BioMed Central Retrieved from the Internet: URL: <http://www.molecularpain.com/content/pdf/1744-8069-4-62.pdf> [retrieved on 2013-04-09]**

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 807 191 B8